SCHEMBL4511159

SCHEMBL4511159

COC(=O)c1cccc(-c2nc(C(=O)c3ccc(N)c(OC)c3)n3cccc(OCCOCCOCCOCCOCCOCCOc4cccn5c(C(=O)c6ccc(N)c(OC)c6)nc(-c6cccc(C(=O)OC)c6)c45)c23)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PDE4D Q08499 2/20 0.35
▸ KDM5B Q9UGL1 1/20 0.35
▸ TNK2 Q07912 5/20 0.34
▸ ADK P55263 1/20 0.34
▸ CDK8 P49336 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ASH1L Q9NR48 1/20 0.33
▸ ERN1 O75460 1/20 0.33
▸ PDPK1 O15530 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ AKT2 P31751 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511201 0.97 KDM4E (0.35) ALDH1A1MAPTKDM4ELMNAHPGD
SCHEMBL1573291 0.93 TNK2 (0.37) ALDH1A1MAPTKDM4ELMNAPDE4D
SCHEMBL4496043 0.87 PDE4D (0.38) MAPTPDE4DKDM5BTNK2ADK
SCHEMBL4511181 0.84 SYK (0.36) ALDH1A1MAPTKDM4ELMNAHPGD
SCHEMBL1931204 0.81 RORC (0.43) MAPTPDE4DKDM5BNPC1RAB9A
SCHEMBL1573295 0.79 TNK2 (0.35) MAPTLMNAPDE4DTNK2NPC1
SCHEMBL1573248 0.79 TNK2 (0.38) MAPTKDM4ELMNAPDE4DTNK2
SCHEMBL13918692 0.79 GAA (0.39) MAPTHPGDPDE4D
SCHEMBL4509705 0.77 PDE4D (0.38) MAPTKDM4ELMNAHPGDSMN1; SMN2
SCHEMBL1573043 0.75 LMNA (0.36) ALDH1A1MAPTKDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 — — US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 ALDH1A1 1044/4885MAPT 3588/4885KDM4E 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback